X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 15, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15

Reporting Person: Bill & Melinda Gates Foundation (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Convertible Preferred Stock	$		Common Stock (722179)		Direct

Footnotes

F1: The Series D Convertible Preferred Stock is convertible at any time, at the holder's election and automatically upon the closing of the issuer's initial public offering, on a 0.29300-for-one basis and has no expiration date.